Cedars-Sinai named among ‘Hospitals with Great Orthopaedic Programs’ Cedars-Sinai’s Orthopaedic Center is one of only 60 hospitals nationwide to be named among the Hospitals with Great Orthopaedic Programs, a distinction awarded by Becker’s Hospital Review, a national magazine focused on healthcare management and services. Cedars-Sinai’s system was recognized for its excellence in all regions of orthopaedics, including quality of service, number of methods performed and a superb local and national status. Earlier this year, Cedars-Sinai’s orthopaedic plan was named among the top in the united states by U cliquez pour être lié .S.
.. Celator presents new data on CPX-351 liposome injection in European Hematology Association congress Celator Pharmaceuticals today announced that new data from a preclinical leukemia research in mice demonstrate that its lead product, CPX-351 Liposome Injection, alone or in conjunction with clofarabine or azacytidine may improve treatment outcomes compared to the combination of either agent with the conventional cytarabine:daunorubicin regimen. As prior research has demonstrated, the task of combining cytarabine:daunorubicin with additional anti-leukemic agents is definitely that the dosing modifications necessary to avoid unacceptable toxicities may compromise treatment efficacy, stated Lawrence Mayer, PhD, president and head of research at Celator Pharmaceuticals.